In Section A, contributors will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More participants is going to be enrolled at the identified monotherapy dosign regimen. In Segment B, members will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase https://abbv-744brd4inhibitioninc02579.activablog.com/31271894/5-essential-elements-for-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc